Drug profile · INN
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)
DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL
- Patents linked
- 0
- News articles
- 0
Quick answer
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran) (DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)
Brand DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL
Frequently asked questions
What is coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)?
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran) (DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)?
DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL is a marketed brand name for coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran). Check FDA Drugs@FDA for the current US label holder and prescribing information.